Business Context and Reporting Period
Company: Akers Biosciences, Inc. (Ticker: AKER)
Filing Type: Form 8-K (Current Report)
Date: August 27, 2020
Context: The filing discloses positive proof of concept results from animal studies regarding the Company's SARS-CoV-2 vaccine candidate, conducted in partnership with Premas Biotech.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure regarding clinical progress rather than financial performance.
Material Changes
- Scientific Milestone: Announcement of positive proof of concept results from a 4-week animal study in mice for the Company's SARS-CoV-2 vaccine candidate.
- Partnership: The study was conducted in collaboration with partner Premas Biotech.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the positive results.
- Forward-Looking Statements: The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this filing.
- Legal Disclaimer: Information provided under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific data points regarding the animal study results.
- Verify the status of the partnership agreement with Premas Biotech.
- Check subsequent filings for updates on the progression of the vaccine candidate from animal studies to human clinical trials.
- Confirm the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not contain financial data.